Accounting policy.

No definition available.

Name:	fgen_AccountingPolicyLineItems
Namespace Prefix:	fgen_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Description of sales return.

+ References

No definition available.

+ Details

Name:	fgen_DescriptionOfSalesReturn
Namespace Prefix:	fgen_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront payment.

+ References

No definition available.

+ Details

Name:	fgen_InitialUpfrontPayment
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum additional future option, clinical, regulatory, and commercial milestone payments.

+ References

No definition available.

+ Details

Name:	fgen_MaximumAdditionalFutureOptionClinicalRegulatoryAndCommercialMilestonePayments
Namespace Prefix:	fgen_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Profit share percent.

+ References

No definition available.

+ Details

Name:	fgen_ProfitSharePercent
Namespace Prefix:	fgen_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name:	us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of liability recognized arising from contingent consideration in a business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 35
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 25
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476

+ Details

Name:	us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599

+ Details

Name:	us-gaap_NumberOfOperatingSegments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Name:	us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_AstraZenecaAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=fgen_HiFiBiOAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Significant Accounting Policies - Additional Information (Detail) shares in Millions		3 Months Ended		6 Months Ended
	Jun. 16, 2021 USD ($)	Jun. 30, 2021 shares	Jun. 30, 2020 shares	Jun. 30, 2021 Segment shares	Jun. 30, 2020 shares
Accounting Policy [Line Items]
Number of operating segment \| Segment				1
Anti-dilutive shares outstanding \| shares		11.4	9.2	9.4	9.0
Description of payment term				The period between the transfer of control of the promised goods and when the Company receives payment is based on 60-day payment terms.
Description of sales return				Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product’s expiration date.
AstraZeneca Agreements [Member]
Accounting Policy [Line Items]
Profit share percent				50.00%
HiFiBiO Agreement [Member]
Accounting Policy [Line Items]
Initial upfront payment	$ 25,000,000.0
Maximum additional future option, clinical, regulatory, and commercial milestone payments	1,100,000,000
Contingent consideration	$ 0